# A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

Source: https://onco.cc/trials/nct06508983/  
OnCo record `nct06508983` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing SG301 in multiple myeloma, now recruiting.

## Summary

A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients is a phase 3 interventional study registered as NCT06508983, led by Hangzhou Sumgen Biotech, and recruiting on the registry. Official title: A Phase 3 Randomised, Placebo-controlled, Double-blind, Multicenter Study Comparing SG301 in Combination With Pomalidomide and Dexamethasone Versus Placebo in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Planned enrolment is 360 participants (estimated). The study started in 2024-06-14 and primary completion is expected in 2027-03-31. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06508983
- Phase: 3
- Setting: A Phase 3 Randomized, Placebo-controlled, Double-blind, Multicenter Study Comparing SG301 in Combination With Pomalidomide and Dexamethasone Versus Placebo in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- Sponsor: Hangzhou Sumgen Biotech
- Enrolled: 360

## Sources

- ClinicalTrials.gov NCT06508983: https://clinicaltrials.gov/study/NCT06508983

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- drugs: [SG301](https://onco.cc/drugs/sg301/)
- companies: [Hangzhou Sumgen Biotech](https://onco.cc/companies/hangzhou-sumgen-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct06508983.json